Render Target: SSR
Render Timestamp: 2024-10-24T19:15:59.034Z
Commit: 56767fe525c928647c8401233a175d0d607d385d
XML generation date: 2024-10-07 13:58:09.388
Product last modified at: 2024-10-09T10:00:10.312Z
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

Dibutyryl-cAMP (sodium salt) #35857

    Product Information

    Product Usage Information

    Dibutyryl-cAMP (sodium salt) is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 5 mg of powder in 1.02 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 491.4 g/mol
    Purity >97%
    Molecular Formula C18H23N5O8P • Na
    CAS 16980-89-5
    Solubility Soluble in DMSO at 50 mg/mL or water at 50 mg/mL.

    Background

    Dibutyryl-cAMP (sodium salt), also known as bucladesine, is an analog of the second messenger cyclic adenosine 3'5'-monophosphate (cAMP). Dibutyryl-cAMP is a phosphodiesterase (PDE) inhibitor and a cAMP-dependent protein kinase (PKA) activator that mimics the action of cAMP in cells (1). The anti-inflammatory activity of Dibutyryl-cAMP makes it an option for the treatment of skin inflammation (2). Exposure of rat glial cells to Dibutyryl-cAMP inhibited cell growth and increased glial fibrillary acidic protein levels, resulting in a change toward an astrocytic phenotype (3). Treatment of rat hepatocytes with Dibutyryl-cAMP suppressed both iNOS mRNA and protein expression, decreased iNOS promoter activity, and reduced DNA binding of the transcription factor NF-κB (4). Dibutyryl-cAMP treatment increased phosphorylated cAMP-response element-binding protein (p-CREB) via protein kinase A (PKA) signaling in rat pulmonary fibroblasts. Cells treated with Dibutyryl-cAMP exhibited a reduced number and size of silicosis nodules, and inhibited myofibroblast differentiation and extracellular matrix deposition (5).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.